Taysha Gene Therapies, Inc.
- Last sale
- Oct 23, 2026 · -1.12%
- Market cap
- $1.29B
- 325.88M shares
- Filings
- 404
Q3 2026+17.3% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026+130.0% FY25 yoy
- $1.29B
- —
- 235.6×
- 3.6×
- -10.96%
- —
Twelve months to Sep 30, 2026 · derived
Price
Oct 23, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $9,773,000 | reported | |
| FY 2024 | 2024-12-31 | $8,333,000 | reported | |
| FY 2023 | 2023-12-31 | $15,451,000 | reported | |
| FY 2022 | 2022-12-31 | $2,502,000 | reported |
Biological products, except diagnostic substances
Taysha Gene Therapies, Inc. is the 63rd largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836
CompanyRevenueGrowthNet marginMarket cap
RLAYRelay Therapeutics, Inc.$15.4M53.4%1,800.6%$4.0BLCTXLineage Cell Therapeutics, Inc.$14.6M53.2%436.5%$250.5MELUTElutia Inc.$12.3M15.0%434.2%$39.8MCRBUCaribou Biosciences, Inc.$11.2M11.7%1,327.4%$40.8MTCRXTScan Therapeutics, Inc.$10.3M266.7%1,256.8%$11.1MACOGAlpha Cognition Inc.$10.2M—202.2%$188.3M
TSHATaysha Gene Therapies, Inc. (this company)$9.8M17.3%1,115.3%$1.3B
CRISCuris Inc$9.4M13.4%80.3%$5.5MFATEFate Therapeutics Inc$6.6M51.2%2,051.1%$161.7MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Taysha Gene Therapies, Inc. · CIK 1806310 · Engraved from SEC EDGAR